June 9, 2023
MarketScreener
AMGEN TO PRESENT AT THE GOLDMAN SACHS 44TH ANNUAL GLOBAL HEALTHCARE CONFERENCE
(marketscreener.com) THOUSAND OAKS, Calif., June 9, 2023 /PRNewswire/ -- Amgen will present at the Go... See more »
InflaRx: InflaRx Reports Full Year 2022 Financial and Operating Results
InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced financial and operating results for the year ended December 31, 2022.
Read full article »
June 9, 2023
MarketScreener
Regeneron Pharmaceuticals : Q1 2023 Earnings Conference Call Transcript
(marketscreener.com) REFINITIVSTREETEVENTS EDITED TRANSCRIPT REGN.OQ - Q1 2023 Regeneron Pharmaceutic... See more »
June 9, 2023
MarketScreener
AMGEN TO PRESENT AT THE GOLDMAN SACHS 44TH ANNUAL GLOBAL HEALTHCARE CONFERENCE
(marketscreener.com) THOUSAND OAKS, Calif., June 9, 2023 /PRNewswire/ -- Amgen will present at the Go... See more »
June 9, 2023
MarketScreener
Regeneron Pharmaceuticals : Q1 2023 Earnings Conference Call Transcript
(marketscreener.com) REFINITIVSTREETEVENTS EDITED TRANSCRIPT REGN.OQ - Q1 2023 Regeneron Pharmaceutic... See more »
InflaRx is a Germany-based biopharmaceutical company that develops monoclonal antibodies for the treatment of inflammatory diseases.
Read more